Lepu Medical Tech Beijing vs Guangzhou Wondfo Biotech: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Lepu Medical Tech Beijing (300003.CS)

Q3 202615 Jul – 8 Oct 2026

▲3▼1

Lepu's profit slump meets a wave of obesity-drug trial wins

Profit and sales fell as procurement squeezed prices First-half 2026 revenue slipped 4.6% and net profit dropped about 28% from a year earlier, with the second quarter also weaker. Management blames government bulk-buying (procurement) that forces down prices on its medical consumables and generic drugs. Falling profit and margins weigh on the share price.
The core earnings deterioration is the main drag on the stock and the backdrop for everything else.
Obesity and muscle-preserving drug pipeline advances Two experimental obesity shots from subsidiary Shanghai Minwei won Chinese clinical trial approval: MWN110, an antibody that cuts fat while preserving muscle, and MWN117, a longer-acting treatment. Neither has any approved rival worldwide yet. This optional new growth story supports the share price even though sales are years away.
The pipeline is the main positive force offsetting the weak core business.
US FDA clears both obesity drugs for trials The US drug regulator agreed to let Lepu test MWN110 and MWN117 in clinical trials, opening a path to the huge American market. Both already had Chinese approval. This global validation raises the pipeline's potential value, though trials are early and could still fail.
US clearance is a fresh, concrete step that lifts the value of the pipeline story.
Dividend and chairman buying signal confidence Lepu will pay a cash dividend of about 1.63 yuan per 10 shares, roughly 300 million yuan total, and the chairman bought more shares at about 11.71 yuan, promising not to sell for six months. These moves put cash in shareholders' hands and show insider belief in the company's value.
Payout and insider buying are tangible supports for investor sentiment amid the profit decline.

August 202615 Jul – 8 Oct 2026

▲3▼1

Lepu's profit slump meets a wave of obesity-drug trial wins

Profit and sales fell as procurement squeezed prices First-half 2026 revenue slipped 4.6% and net profit dropped about 28% from a year earlier, with the second quarter also weaker. Management blames government bulk-buying (procurement) that forces down prices on its medical consumables and generic drugs. Falling profit and margins weigh on the share price.
The core earnings deterioration is the main drag on the stock and the backdrop for everything else.
Obesity and muscle-preserving drug pipeline advances Two experimental obesity shots from subsidiary Shanghai Minwei won Chinese clinical trial approval: MWN110, an antibody that cuts fat while preserving muscle, and MWN117, a longer-acting treatment. Neither has any approved rival worldwide yet. This optional new growth story supports the share price even though sales are years away.
The pipeline is the main positive force offsetting the weak core business.
US FDA clears both obesity drugs for trials The US drug regulator agreed to let Lepu test MWN110 and MWN117 in clinical trials, opening a path to the huge American market. Both already had Chinese approval. This global validation raises the pipeline's potential value, though trials are early and could still fail.
US clearance is a fresh, concrete step that lifts the value of the pipeline story.
Dividend and chairman buying signal confidence Lepu will pay a cash dividend of about 1.63 yuan per 10 shares, roughly 300 million yuan total, and the chairman bought more shares at about 11.71 yuan, promising not to sell for six months. These moves put cash in shareholders' hands and show insider belief in the company's value.
Payout and insider buying are tangible supports for investor sentiment amid the profit decline.

Latest15 Jul – 8 Oct 2026

▲3▼1

Lepu's profit slump meets a wave of obesity-drug trial wins

Profit and sales fell as procurement squeezed prices First-half 2026 revenue slipped 4.6% and net profit dropped about 28% from a year earlier, with the second quarter also weaker. Management blames government bulk-buying (procurement) that forces down prices on its medical consumables and generic drugs. Falling profit and margins weigh on the share price.
The core earnings deterioration is the main drag on the stock and the backdrop for everything else.
Obesity and muscle-preserving drug pipeline advances Two experimental obesity shots from subsidiary Shanghai Minwei won Chinese clinical trial approval: MWN110, an antibody that cuts fat while preserving muscle, and MWN117, a longer-acting treatment. Neither has any approved rival worldwide yet. This optional new growth story supports the share price even though sales are years away.
The pipeline is the main positive force offsetting the weak core business.
US FDA clears both obesity drugs for trials The US drug regulator agreed to let Lepu test MWN110 and MWN117 in clinical trials, opening a path to the huge American market. Both already had Chinese approval. This global validation raises the pipeline's potential value, though trials are early and could still fail.
US clearance is a fresh, concrete step that lifts the value of the pipeline story.
Dividend and chairman buying signal confidence Lepu will pay a cash dividend of about 1.63 yuan per 10 shares, roughly 300 million yuan total, and the chairman bought more shares at about 11.71 yuan, promising not to sell for six months. These moves put cash in shareholders' hands and show insider belief in the company's value.
Payout and insider buying are tangible supports for investor sentiment amid the profit decline.

Guangzhou Wondfo Biotech Co Ltd (300482.CS)

Q3 202625 Jul – 23 Aug 2026

▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.
Explains the main force behind the stock's slump and why investors are worried.
Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.
Shows concrete capital actions that counter the negative news and support the stock.
First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.
This is the key new evidence that the business is recovering, directly answering why the stock may be moving.
Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.
Shows new product momentum that could drive future growth, a fresh positive for the stock.

August 202625 Jul – 23 Aug 2026

▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.
Explains the main force behind the stock's slump and why investors are worried.
Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.
Shows concrete capital actions that counter the negative news and support the stock.
First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.
This is the key new evidence that the business is recovering, directly answering why the stock may be moving.
Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.
Shows new product momentum that could drive future growth, a fresh positive for the stock.

Latest25 Jul – 23 Aug 2026

▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.
Explains the main force behind the stock's slump and why investors are worried.
Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.
Shows concrete capital actions that counter the negative news and support the stock.
First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.
This is the key new evidence that the business is recovering, directly answering why the stock may be moving.
Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.
Shows new product momentum that could drive future growth, a fresh positive for the stock.